The 4th edition of HealthTech Innovation Days (HTID), was held in-person in Paris along with a virtual platform on 13-14 October. The event brought together more than 165 European health technology companies, 15 pharmaceutical and industrial companies and over 300 international investors. Eighty-six international experts lead 19 round table discussions which can be viewed online here: https://htfc-eu.com/htid/htid4-replay/ .

HTID was organized by HealthTech For Care to bring together key stakeholders of the European ecosystem of innovation in health with the objective of finding financing and encouraging new industrial partnerships to accelerate the development and market access of new products and treatments for patients.

“Europe has a strong network of hundreds of companies with ambitious innovations in the field of health. To develop their products and services, access the market and make them available to patients, these companies need massive financial support. As the only European event to bring together all the players in the healthtech eco-
system, the HTID once again confirms its mission to serve the growth of these companies and will continue to strengthen its commitment in the years to come,” said Maryvonne Hiance, chairwomen of HealthTech For Care, organizer of the HTID.

Hubert Gambs, Deputy Director General DG GROW – Internal Market, Industry, Entrepreneurship and SMEs – at the European Commission, noted: “The 4.1% increase in healthcare spending in 2022 is structurally higher than global GDP growth and highlights the long-term trends that are still intact and are the fundamental drivers of healthcare markets: the increase in the world’s population, its ageing, the constant progress of medical treatments combined with the expansion of public healthcare systems. The European Commission wants to have Europe as a preferred location for life sciences. Among the many initiatives taken is the Important Project of Common European Interest (IPCEI) in the area of health, a key strategic instrument that brings together expertise, financial resources, and economic actors to overcome market failures and societal challenges. Also worth mentioning is the European Commission’s ongoing work on intellectual property rights with the imminent launch of the Unitary Patent system to support EU competitiveness. Europe’s success in health innovation is a long-term objective, serving the EU’s economic success and strategic autonomy.”

HealthTech For Care Innovation Award
The HealthTech For Care Innovation Award, introduced for the first time during this 4th edition of the HTID, gave the opportunity to 25 HealthTech companies (Biotech, MedTech, Innovative Services & Digital Health), from seven countries and selected by the European clusters, to present their solutions to health experts and investors during a pitch competition.
The winners of this first edition are :
• 1st Prize: MRM Health is a biopharmaceutical company specialized in the discovery and development of innovative therapies based on the human microbiome. The company is based in a centre of expertise for microbiome research and development in Belgium.
• 2nd Prize: FluoSphera is developing technology to better predict the effects of molecules to help biotech and pharmaceutical companies discover more effective drugs with fewer adverse side effects and reduce animal testing. The company is based in Switzerland.
• 3rd Prize: Vidac Pharma is a biopharmaceutical company dedicated to the discovery and development of innovative drugs to help people suffering from various oncological and dermatological diseases. Its work focuses on the tumour micro environment.

The winner was awarded the “HealthTech For Care Innovation” prize, which provides privileged connections with HTFC’s sponsors, visibility through dedicated communication and free access to the 5th edition of HTID.

HealthTech For Care endowment fund
The HealthTech For Care endowment fund is designed to support and promote access to healthcare for all, and more specifically to new medical technologies and medicines. The missions of the endowment fund are organised around three main areas: to support the development of the entire healthcare ecosystem, to accelerate the development of innovative therapies and medicines, and to promote better access for patients to the healthcare system in France and Europe.

HealthTech For Care benefits from the support of its founder France Biotech and the network of French health clusters: Atlanpole biotherapies, BioValley France, EuroBioMed, LyonBioPole, Medicen and the NSL cluster. The endowment fund is also supported by many European businesses and organisations, including: Asebio, BioAlps, BIO Deutschland, BioIndustry Association, BioWin, CEBR, Federchimica Assobiotec, flanders.bio, HollandBIO, IREFI, Medvia, Swiss Biotech and French: Business France.

For more information, visit: https://htfc-eu.com/htid/